Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting performance compared to conventional treatments. However, the unsatisfactory response rates, high recurrence and adaptive resistance limit the...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yaolin, He, Lijie, Fu, Qiang, Hu, Junzhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632143/
https://www.ncbi.nlm.nih.gov/pubmed/34858835
http://dx.doi.org/10.3389/fonc.2021.759015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632143/
https://www.ncbi.nlm.nih.gov/pubmed/34858835
http://dx.doi.org/10.3389/fonc.2021.759015

Ejemplares similares